NBRV logo

Nabriva Therapeutics (NBRV) Cash From Investing

Annual CFI

-$263.00 K
-$182.00 K-224.69%

December 31, 2022

Summary

Performance

1-Year Change

-224.69%

3-Year Change

-179.46%

5-Year Change

-100.53%

15-Year Change

-100.53%

NBRV Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$49.75 M
NBRV annual cash flow from investing activities is currently -100.53% below its historical high of $49.75 million

3-Year Low

-$263.00 K
NBRV annual cash flow from investing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
NBRV previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
NBRV next annual earnings announcement has not yet been scheduled

OtherNBRVcash flowmetrics:

Annual CFF

$1.85 M
NBRV annual cash flow from financing activities is $1.85 million

Annual CFO

-$36.71 M
NBRV annual cash flow from operations is -$36.71 million

Annual FCF

-$36.92 M
NBRV annual free cash flow is -$36.92 million

Annual CAPEX

$211.00 K
NBRV annual capital expenditures is $211.00 thousand

Quarterly CFI

-$3000.00
+$4000.00+57.14%

March 31, 2023

Summary

Performance

3-Month Change

+57.14%

1-Year Change

+91.67%

3-Year Change

+85%

5-Year Change

+98.12%

NBRV Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$31.59 M
NBRV quarterly cash flow from investing activities is currently -100.01% below its historical high of $31.59 million

3-Year Low

-$116.00 K

Earnings dates

Last Quarterly Earnings Report Date

Mar 31, 2023
NBRV previous earnings announcement was published on Mar 31, 2023

Next Quarterly Earnings Report Date

N/A
NBRV next earnings announcement has not yet been scheduled

OtherNBRVcash flowmetrics:

Quarterly CFF

-$4.85 M
NBRV quarterly cash flow from financing activities is -$4.85 million

Quarterly CFO

-$5.62 M
NBRV quarterly cash flow from operations is -$5.62 million

Quarterly FCF

-$5.62 M
NBRV quarterly free cash flow is -$5.62 million

Quarterly CAPEX

$3000.00
NBRV quarterly capital expenditures is $3000.00

TTM CFI

-$230.00 K
+$33.00 K+12.55%

March 31, 2023

Summary

Performance

3-Month Change

+12.55%

1-Year Change

-7766.67%

3-Year Change

-165.16%

5-Year Change

-169.49%

NBRV TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$49.75 M
NBRV TTM cash flow from investing activities is currently -100.46% below its historical high of $49.75 million

3-Year Low

-$268.00 K

Earnings dates

Last Quarterly Earnings Report Date

Mar 31, 2023
NBRV previous earnings announcement was published on Mar 31, 2023

Next Quarterly Earnings Report Date

N/A
NBRV next earnings announcement has not yet been scheduled

OtherNBRVcash flowmetrics:

TTM CFF

-$5.20 M
NBRV TTM cash flow from financing activities is -$5.20 million

TTM CFO

-$26.46 M
NBRV TTM cash flow from operations is -$26.46 million

TTM FCF

-$26.64 M
NBRV TTM free cash flow is -$26.64 million

TTM CAPEX

$179.00 K
NBRV TTM capital expenditures is $179.00 thousand

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

NBRV Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-224.7%+91.7%-7766.7%
3 y3 years-179.5%+85.0%-165.2%
5 y5 years-100.5%+98.1%-169.5%

NBRV Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+224.7%at lowat high+3766.7%-7766.7%+16.5%
5 y5-year-179.5%+4.2%-101.5%+7500.0%-165.2%+62.6%
alltimeall time-100.5%>+9999.0%-100.0%>+9999.0%-100.5%>+9999.0%

Nabriva Therapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Mar 2023
-
-$3000.00(-57.1%)
-$230.00 K(-12.5%)
Dec 2022
-$263.00 K(+224.7%)
-$7000.00(-93.3%)
-$263.00 K(-1.9%)
Sep 2022
-
-$104.00 K(-10.3%)
-$268.00 K(+63.4%)
Jun 2022
-
-$116.00 K(+222.2%)
-$164.00 K(-5566.7%)
Mar 2022
-
-$36.00 K(+200.0%)
$3000.00(-103.7%)
Dec 2021
-$81.00 K(-70.4%)
-$12.00 K(<-9900.0%)
-$81.00 K(-5.8%)
Sep 2021
-
$0.00(-100.0%)
-$86.00 K(-9.5%)
Jun 2021
-
$51.00 K(-142.5%)
-$95.00 K(-74.6%)
Mar 2021
-
-$120.00 K(+605.9%)
-$374.00 K(+36.5%)
Dec 2020
-$274.00 K(-182.8%)
-$17.00 K(+88.9%)
-$274.00 K(+380.7%)
Sep 2020
-
-$9000.00(-96.1%)
-$57.00 K(-140.7%)
Jun 2020
-
-$228.00 K(+1040.0%)
$140.00 K(-60.3%)
Mar 2020
-
-$20.00 K(-110.0%)
$353.00 K(+6.6%)
Dec 2019
$331.00 K(-107.2%)
$200.00 K(+6.4%)
$331.00 K(-437.8%)
Sep 2019
-
$188.00 K(-1353.3%)
-$98.00 K(-97.8%)
Jun 2019
-
-$15.00 K(-64.3%)
-$4.38 M(-2.4%)
Mar 2019
-
-$42.00 K(-81.7%)
-$4.49 M(-2.6%)
Dec 2018
-$4.60 M
-$229.00 K(-94.4%)
-$4.60 M(+15.5%)
Sep 2018
-
-$4.09 M(+3226.8%)
-$3.99 M(-112.6%)
DateAnnualQuarterlyTTM
Jun 2018
-
-$123.00 K(-23.1%)
$31.70 M(-20.0%)
Mar 2018
-
-$160.00 K(-141.2%)
$39.61 M(-20.4%)
Dec 2017
$49.75 M(+113.0%)
$388.00 K(-98.8%)
$49.75 M(+5.4%)
Sep 2017
-
$31.59 M(+305.6%)
$47.18 M(+85.6%)
Jun 2017
-
$7.79 M(-21.9%)
$25.43 M(-16.4%)
Mar 2017
-
$9.98 M(-557.2%)
$30.40 M(+30.2%)
Dec 2016
$23.35 M(-130.4%)
-$2.18 M(-122.2%)
$23.35 M(-145.8%)
Sep 2016
-
$9.84 M(-22.9%)
-$51.03 M(-16.3%)
Jun 2016
-
$12.76 M(+335.0%)
-$60.94 M(-17.3%)
Mar 2016
-
$2.93 M(-103.8%)
-$73.73 M(-3.9%)
Dec 2015
-$76.70 M(>+9900.0%)
-$76.57 M(>+9900.0%)
-$76.70 M(>+9900.0%)
Sep 2015
-
-$69.00 K(+146.4%)
-$210.00 K(+47.2%)
Jun 2015
-
-$28.00 K(-30.0%)
-$142.70 K(+18.8%)
Mar 2015
-
-$40.00 K(-45.2%)
-$120.10 K(+38.0%)
Dec 2014
-$87.00 K(-102.5%)
-$73.00 K(+4194.1%)
-$87.00 K(+521.4%)
Sep 2014
-
-$1700.00(-68.5%)
-$14.00 K(+13.8%)
Jun 2014
-
-$5400.00(-21.7%)
-$12.30 K(+78.3%)
Mar 2014
-
-$6900.00
-$6900.00
Dec 2013
$3.42 M
-
-

FAQ

  • What is Nabriva Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Nabriva Therapeutics?
  • What is Nabriva Therapeutics annual CFI year-on-year change?
  • What is Nabriva Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Nabriva Therapeutics?
  • What is Nabriva Therapeutics quarterly CFI year-on-year change?
  • What is Nabriva Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Nabriva Therapeutics?
  • What is Nabriva Therapeutics TTM CFI year-on-year change?

What is Nabriva Therapeutics annual cash flow from investing activities?

The current annual CFI of NBRV is -$263.00 K

What is the all time high annual CFI for Nabriva Therapeutics?

Nabriva Therapeutics all-time high annual cash flow from investing activities is $49.75 M

What is Nabriva Therapeutics annual CFI year-on-year change?

Over the past year, NBRV annual cash flow from investing activities has changed by -$182.00 K (-224.69%)

What is Nabriva Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of NBRV is -$3000.00

What is the all time high quarterly CFI for Nabriva Therapeutics?

Nabriva Therapeutics all-time high quarterly cash flow from investing activities is $31.59 M

What is Nabriva Therapeutics quarterly CFI year-on-year change?

Over the past year, NBRV quarterly cash flow from investing activities has changed by +$33.00 K (+91.67%)

What is Nabriva Therapeutics TTM cash flow from investing activities?

The current TTM CFI of NBRV is -$230.00 K

What is the all time high TTM CFI for Nabriva Therapeutics?

Nabriva Therapeutics all-time high TTM cash flow from investing activities is $49.75 M

What is Nabriva Therapeutics TTM CFI year-on-year change?

Over the past year, NBRV TTM cash flow from investing activities has changed by -$233.00 K (-7766.67%)